Lab
Precision Diagnostics LLC
Precision Diagnostics LLC was paid $4.72M by Medicaid between Jan 2018 and Dec 2024, across 75 billing codes. Its largest line is 0202U, Oncology (prostate), multianalyte, gene expression profiling — 28% of everything it billed.
33Billing provider infoPRECISION DIAGNOSTICS LLC
LAFAYETTE, LA 70506
LAFAYETTE, LA 70506
33aNPI1851693220assigned 11/17/2010
33bProvider typeClinical Medical Laboratory
28Total paid$4.72M
24GClaims167,293
24DCodes billed75
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Louisiana
Rank by total paid#13 of 66
Median peer was paid$253K
This provider vs. median19×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,853 | $313K | |
| 2019 | 9,342 | $228K | |
| 2020 | 10,993 | $289K | |
| 2021 | 18,273 | $821K | |
| 2022 | 26,549 | $1.31M | |
| 2023 | 50,250 | $1.07M | |
| 2024incomplete | 39,033 | $689K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 28% | 3,692 | 3,260 | $1.34M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 16% | 30,560 | 25,957 | $778K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 16% | 30,511 | 25,946 | $777K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 11% | 22,543 | 19,598 | $523K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 11% | 21,955 | 17,991 | $521K |
| 87150 | 2.6% | 4,982 | 4,296 | $123K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 1.9% | 983 | 644 | $92K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.9% | 1,398 | 1,258 | $91K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 445 | 404 | $43K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,370 | 2,020 | $42K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,433 | 1,193 | $28K |
| 87481 | <1% | 1,818 | 1,646 | $27K |
63 more codes
| 87625 | <1% | 1,461 | $27K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 4,417 | $26K |
| 87511 | <1% | 1,605 | $25K | |
| 86803 | <1% | 2,132 | $23K | |
| 86762 | <1% | 2,119 | $23K | |
| 87081 | <1% | 4,929 | $23K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 368 | $19K |
| 87340 | <1% | 2,104 | $17K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,476 | $15K |
| 86593 | <1% | 3,526 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 798 | $9K |
| 84144 | <1% | 566 | $9K | |
| 86850 | <1% | 2,164 | $9K | |
| 83020 | <1% | 825 | $8K | |
| 82950 | <1% | 1,740 | $6K | |
| 84703 | <1% | 1,183 | $6K | |
| 87507 | <1% | 31 | $6K | |
| 86900 | <1% | 2,184 | $5K | |
| 86901 | <1% | 2,161 | $5K | |
| 81514 | <1% | 54 | $4K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 187 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 474 | $4K |
| 82670 | <1% | 145 | $3K | |
| 80053 | Comprehensive metabolic panel | <1% | 484 | $3K |
| 83001 | <1% | 179 | $3K | |
| 84403 | <1% | 116 | $2K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 45 | $2K |
| 84402 | <1% | 113 | $2K | |
| 84439 | <1% | 325 | $2K | |
| 83727 | <1% | 159 | $2K | |
| 82951 | <1% | 291 | $2K | |
| 83525 | <1% | 206 | $2K | |
| 86038 | <1% | 176 | $2K | |
| 84146 | <1% | 113 | $2K | |
| 82575 | <1% | 207 | $2K | |
| 82533 | <1% | 108 | $1K | |
| 82626 | <1% | 62 | $1K | |
| 85660 | <1% | 275 | $1K | |
| 86304 | <1% | 80 | $1K | |
| 83498 | <1% | 63 | $1K | |
| 82330 | <1% | 95 | $909.08 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 76 | $844.56 |
| 82952 | <1% | 287 | $755.46 | |
| 84156 | <1% | 245 | $694.33 | |
| 81001 | <1% | 540 | $657.28 | |
| 84550 | <1% | 175 | $625.83 | |
| 83615 | <1% | 119 | $570.95 | |
| 82947 | <1% | 433 | $488.75 | |
| 84702 | <1% | 39 | $449.10 | |
| 87186 | <1% | 72 | $367.79 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 12 | $345.51 |
| 87653 | <1% | 15 | $315.81 | |
| 82570 | <1% | 304 | $313.31 | |
| 87529 | <1% | 14 | $280.72 | |
| 80061 | Lipid panel | <1% | 26 | $261.36 |
| 86696 | <1% | 17 | $232.20 | |
| 36416 | <1% | 220 | $197.34 | |
| 84481 | <1% | 26 | $186.58 | |
| 86695 | <1% | 17 | $157.68 | |
| 85014 | <1% | 45 | $98.73 | |
| 82565 | <1% | 228 | $30.54 | |
| 84436 | <1% | 57 | $9.62 | |
| 81511 | 0% | 890 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWEST, JASON (ADMINISTRATOR)